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388 Detection of a novel CFTR mutation c.122C>G (p.Pro41Arg) in
a young cystic ﬁbrosis (CF) patient with recurrent respiratory
symptoms
E. De Wachter1, I. De Schutter1, A. Malfroot1, S. Van Dooren2, K. Claes3. 1UZ
Brussel, CF Clinic, Brussels, Belgium; 2UZ Brussel, Dept. Genetics, Brussels,
Belgium; 3Ghent University Hospital, Center for Medical Genetics, Ghent,
Belgium
Background: At present more than 1800 mutations have been described in the
CFTR-gene. Several rare mutations are believed to cause mild lung disease and
late onset of symptoms. We present a 5 y old Belgian boy heterozygous for an
atypical CFTR variant and a novel variant which was never described before.
Case report: A 5 y old boy with recurrent bronchitis and chronic sinusitis was
referred to our clinic with repeated abnormal sweat chloride (Cl) (right 70mEq/L;
left 53mEq/L) and elevated sweat sodium values (right 86mEq/L; left 62mEq/L),
performed by Gibson and Cooke gauze method. Chest CT scan showed bronchial
wall thickening and mucous plugging, without bronchiectasis. He is pancreatic
sufﬁcient, without history of pancreatitis. By screening the coding region of CFTR,
using sequencing and MLPA (Multiplex Ligation-dependent Probe Ampliﬁcation),
he was shown to be heterozygous for c.224G>A (p.Arg75Gln − legacy name:
R75Q) and c.122C>G (p.Pro41Arg), a novel variant which was never described
before. Analysis of the parents is ongoing to prove that both variants are on different
alleles.
Discussion: R75Q is described as a variant overrepresented in patients with atypi-
cal CF, sarcoidosis, COPD and chronic pancreatitis and rather inﬂuences bicarbonate
conductance than Cl. Our young patient has already respiratory symptoms and
abnormal sweat chloride values. To our knowledge CFTR p.Pro41Arg has never
been described before and its clinical relevance is not clear. As this boy has signs
and symptoms of CF disease in combination with an atypical CFTR mutation, this
novel mutation might be involved. However, mutations outside the coding region
cannot be excluded.
389 Prolonged Clostridium difﬁcile associated diarrhoea in a
cystic ﬁbrosis patient precluding suitability for lung transplant:
an important issue for patients awaiting transplantation
D.J. O’Brien1, K. Schaffer1, E. Mc Kone2, C. Gallagher2. 1St. Vincent’s University
Hospital, Microbiology, Dublin, Ireland; 2St. Vincent’s University Hospital,
Respiratory Medicine, Dublin, Ireland
A 21 year old man with cystic ﬁbrosis and declining lung function was assessed for
suitability for lung transplant. His sputum was culture positive for Pseudomonas
aeruginosa, Stenotrophomonas maltophilia and methicillin resistant Staphylococcus
aureus for which he received multiple courses of broad-spectrum antibiotics in-
cluding meropenem, ceftazidime, linezolid, tobramycin, teicoplanin and colistin. In
the interim he developed Clostridium difﬁcile associated diarrhoea (CDAD) which
failed to respond to courses of oral metronidazole and oral vancomycin. A course of
pulsed oral vancomycin was administered. This resulted in resolution of symptoms
but follow up faecal cultures were found to be positive for Clostridium difﬁcile and
he was deemed not to be a suitable candidate for lung transplantation.
Deaths directly attributable to CDAD have been described in the CF population
following transplantation. Outbreaks of CDAD have increased in incidence in
healthcare facilities worldwide, in particular linked to the emergence of hyper-
virulent strains. The necessity for multiple, prolonged courses of broad-spectrum
antimicrobials in CF patients makes them a group which are potentially vulnerable
to the development of CDAD.
Further research is urgently required to ascertain the relationship between CDAD
and the CF patient. In the interim it is of paramount importance that infection
prevention and control standards are implemented and maintained to prevent cross
transmission and emergence of new cases of CDAD in the CF population.
390 Efﬁcacy and safety of colistin for inhalation in children 5 years
old and younger with cystic ﬁbrosis with Pseudomonas
aeruginosa infection
V. Nikonova1, E. Zhekayte1, N. Kapranov1. 1Reseach Center for Medical Genetics
RAMS, Cystic Fibrosis, Moscow, Russian Federation
Aim: To estimate the colistin effectiveness and safety for treatment of children
5 years old and younger with cystic ﬁbrosis (CF) and chronic Pseudomonas
aeruginosa (PA) infection.
Method: There were 10 children 5m to 4 y 9m, average 2 y 3m with CF conﬁrm
diagnosis and having PA in sputum. 2 had chronic PA infection and 8 children
had ﬁrst isolate, 4 girls and 6 boys. They were 1 year follow up. The follow-
ing characteristics were estimated in time of research: the physical development
characteristic (weight/height indicator), the rate of exacerbations, examination of
sputum (monthly during half year and every 3 months further). The patients with
ﬁrst isolate were taking colistin inhalation during 21 day (1mln ×2 times/day) +
ciproﬂoxacin therapy (30mg/kg/24 h), the patients with chronically PA infection
colistin inhalation constantly (in the same dose).
Result: We was noted weight/height increasing average 2 kg/7.6 sm during the
treatment. There were no exacerbations, the respiratory syndrome of all patients
were signiﬁcantly reduce. During the examination children with ﬁrst isolate: PA
eradication in 6 case of 8; 1 case PA was revealed in repeated sputum test (sputum
test was clean after 3 months colistin course); 1 case reducing of PA titre. 2 patients
with chronically PA infection had the clean PA sputum test during the colistin
treatment, and PA in sputum test after colistin repeal. All patients were taking
medicine felt themselves good. Were not observed adverse event.
Conclusion: Equal clinical efﬁciency and safety of colistin was shown and it can
be used by CF patients 5 years old and younger.
391 Temocillin − drug of choice for Burkholderia cepacia?
A. Hollsing1, E. Wenngren1. 1Uppsala CF Centre, KBH, Uppsala, Sweden
Two young women with chronic multi-resistant B. cepacia colonisation, seen
regularly at our centre, have been treated regularly with iv beta-lactam antibacterials
+ tobramycin due to exacerbations. Both are severely sick with a lung function
(FEV1) of around 30% of expected, chronic productive cough and low grade tem-
perature. One is listed for transplant, the other has been transferred for evaluation.
On a licence basis, they were treated with the new semi-synthetic beta-lactam
antibacterial, temocillin (Negaban) in combination with tobramycin, intravenously.
Temocillin has been reported to be very effective against B. cepacia exacerbations.
Both patients were started at the hospital, but had home iv treatment with pre-ﬁlled
Homepump devices causing no problems. Both improved clinically with normal
temperature and less cough. The lung function did however not improve. Two weeks
later the temperature and cough relapsed. With a traditional iv treatment in between,
both had a second iv course, again with clinical improvement. Both are now in for
their third iv treatment again after a traditional treatment in between. Temocillin
intravenously could be the drug of choice for multiresistant B. cepacia patients, but
more studies and experience are warranted.
